Drug Trial Radar · NCT07079267
Olpasiran Expanded Access Program
Last checked: Nov 19, 2026Latest source record: Jul 23, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Available
Enrollment
Not stated
Start
Not stated
Primary completion
Not stated
Sponsor
- Lead sponsor
- AmgenAmgen (AMGN)
- Sponsor type
- Industry
- First posted
- Jul 23, 2025
Design
- Study type
- Expanded access
- Who can join
- from 18 years
Summary
As written by the sponsor on the registry.
Expanded access requests for Olpasiran may be considered for adult participants with elevated Lp(a) and atherosclerotic cardiovascular disease (ASCVD). To request access, use Responsible Party contact information provided in this record.
Conditions
No conditions listed.
Interventions
OlpasiranDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
No primary outcomes listed.
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.